Single User License: $2750
Member Price: FREE
Use code SUMMER at checkout for 50% OFF
Already a member? Login to access this report free.
Report Highlights
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Report Includes
- 15 data tables and 80 additional tables
- An overview of the global market and technologies for next generation cancer diagnostics
- Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
- Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
- Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
- Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.
Report Scope
This research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.
The report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.
An in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.
The market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).
The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | ||||||||||||||||||||||||||||||||
| Forecast period considered | 2022-2027 | ||||||||||||||||||||||||||||||||
| Base year market size | $7.8 billion | ||||||||||||||||||||||||||||||||
| Market size forecast | $15 billion | ||||||||||||||||||||||||||||||||
| Growth rate | CAGR of 11.5% for the forecast period of 2022-2027 | ||||||||||||||||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||||||||||||||||
| Segments covered | Cancer Site, Purpose of Analysis, Test Platform, Region | ||||||||||||||||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||||||||||||||||||||||||
| Companies studied |
|
||||||||||||||||||||||||||||||||
Frequently Asked Questions (FAQs)
- Abbott
- Johnson & Johnson
- Novartis
- Roche
- Termo fisher
Analyst Credentials
Kalyani Kottapenta – Assistant Manager, Life Sciences
Kalyani Kottapenta is a research professional with nine years of experience in the life sciences and healthcare industry. Her expertise in qualitative and quantitative market information, including market dynamics like market sizing, advanced excel based market modeling, data analysis, forecasting, company share analysis, and competitive landscape assessment of the medical device industry, developing custom reports. She holds a master’s degree in Microbiology and a bachelor’s in Biotechnology and Chemistry.
Report Highlights
The global market for next generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9% for the period of 2020-2025.
Report Includes
- 22 data tables and 74 additional tables
- An overview of the global market and technologies for next generation cancer diagnostics
- Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
- Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
- Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
- Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
- Details of the key initiatives and programs related to the next generation cancer diagnostics market
- Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.
Report Highlights
BCC Research estimates the global market for next generation cancer diagnostic as $1.6 billion in 2013. This indication is expected to reach $1.8 billion in 2014 and $10 billion in 2019, registering a compound annual growth (CAGR) of 42.6% over the next five years.
Report Includes
- An overview of the global market for next generation cancer diagnostics and related technologies.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Analyses of the diagnostics market by cancer indication (e.g., breast, colorectal, prostate, etc.), by type of analysis (e.g., gene expression, genotyping, proteomic, etc.), and by diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, and companion diagnostic).
- Examination of each technology format to determine its market status, impact on future market segments, and projected growth through the forecast period.
- Discussion on factors influencing the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses.
- Assessments of the major next generation formats that are likely to become commercialized within the next five years.
- Profiles of companies in the industry as well as a look at corporate alliances.
Report Highlights
The total global annual market for next generation cancer diagnostics was $776 million in 2010, and is growing at a compound annual growth rate (CAGR) of 47%, to reach a forecast market size of $5.3 billion in 2015.
Related Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Multi-Cancer Diagnostic Tests: Global Market Outlook
This report provides an in-depth analysis of the global multi-cancer diagnostic (MCD) test market. It highlights the current and future market potential of the tests along with a detailed analysis of the drivers and challenges in the market. The report includes the company profiles of the key players with detailed information about their product portfolios and pipeline products.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Recent Reports
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
RNAi Technologies and Global Markets
The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.
Metabolomics: Technologies and Global Markets
The global market for metabolomics technologies is expected to grow from $16.4 billion in 2024 and is projected to reach $30.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2024 to 2029.
Global Recombinant Proteins Market
The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.
Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
The global market for polymerase chain reaction for point-of-care diagnostics is expected to grow from $1.6 billion in 2024 to $2.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More